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Background: Anemia is a major risk factor that contributes to mortality in patients
with chronic kidney disease. There is controversy over the optimal hemoglobin (Hb)
target in these patients. This study investigated the association between Hb level
and mortality in a cohort of hemodialysis (HD) patients in Korea.
Methods: This study was a multicenter prospective observational study of mainte-
nance HD patients that was performed for 5 years in western Seoul, Korea. Three
hundred and sixty-two participants were enrolled. Laboratory values and mortality
were accessed every 6 months. Repeated measures of laboratory values in each interval
were averaged to obtain one semiannual mean value. The Hb values were divided into
six groups: (1) Hbo9 g/dL; (2) 9 g/dLrHbo10 g/dL; (3) 10 g/dLrHbo11 g/dL;
(4) 11 g/dLrHbo12 g/dL; (5) 12 g/dLrHbo13 g/dL; and (6) HbZ13 g/dL. We ana-
lyzed the odds ratio for all-cause mortality, based on the Hb group, and adjusted for
demographics and various laboratory values. Statistics were performed with SAS,
version 9.1 software (SAS Institute Inc., Cary, NC, USA).
Results: Mortality odds ratios relative to the reference group (10–11 g/dL) in the fully
adjusted model were 3.61 foro9 g/dL; 3.17 for 9–10 g/dLn; 4.65 for 11–12 g/dLn; 5.50
for 12–13 g/dLn; and 2.05 forZ13 g/dL (n indicates Po0.05).
Conclusion: In this study, a Hb level of 10–11 g/dL was associated with the lowest
mortality among the groups with Hb levelo13 g/dL. Larger interventional trials are
warranted to determine the optimal Hb target for Korean HD patients.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Anemia is a common complication in patients with chronic
kidney disease (CKD), particularly in hemodialysis (HD) patients.15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
y, Department of Internal
8 Guro-dongro, Guro-gu,
.Anemia contributes to symptoms such as fatigue, dyspnea,
reduced exercise tolerance, depression, and cardiovascular con-
sequences (e.g., left ventricular hypertrophy) [1]. Anemia is also
associated with increased rates of hospitalization and mortality in
patients with CKD [2,3]. Many studies have shown the beneﬁcial
effects of anemia treatment such as improved quality of life;
protection against cardiovascular disease [4]; and reduced mor-
tality, morbidity, and hospitalization rates [5] in patients withhrology. Published by Elsevier. This is an open access article under the
Jung et al / Optimal hemoglobin in HD patients 21CKD. Until 2 decades ago, the mainstay of treatment was blood
transfusion and the administration of androgenic anabolic ster-
oids. Since the introduction of erythropoiesis-stimulating agents
(ESAs) in the late 1980s, treatment modalities have undergone
profound changes, which have made it possible to achieve
desirable hemoglobin (Hb) levels in patients with CKD. As a result,
the mean Hb and hematocrit (Hct) levels in patients with CKD,
particularly patients on hemodialysis, increased steadily through
2007 in the United States [6] and through 2006 in Korea [7].
In recent decades, many observational studies and inter-
ventional trials have been performed to deﬁne the target level
of Hb in patients with CKD. Several guidelines for anemia
treatment from international groups and various countries
have been revised for patients with CKD. However, contro-
versy exists over the optimal level of anemia correction. In
addition, there are no guidelines for the care of Korean
patients with CKD—most Korean nephrologists use interna-
tional guidelines, [e.g., the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative (KDOQI) guidelines] [8] or
Kidney Disease: Improving Global Outcomes (KDIGO) guide-
lines [9]. The current recommended target Hb level may not
optimize survival in Korean patients with CKD, particularly in
patients with end-stage renal disease (ESRD).
In view of the current controversy over the target Hb level in
patients with CKD and because of ethnic differences in anemia
in various regions of the world, reporting results from Korean
HD patients can serve as a complementary guide for clinical
nephrologists and as a preliminary study for future work up. We
conducted the present study, and adjusted for potential con-
founders and laboratory values over time, to investigate the
association between Hb levels and mortality in a cohort of
Korean HD patients from dialysis clinics in western Seoul.
Methods
Patients
This study was a multicenter prospective observational study
of maintenance HD patients. It was performed using a cohort
from 10 dialysis clinics in western Seoul between September
2006 and September 2011. We included patients who were older
than 18 years and had been on HD for43 months in September
2006. Patients with malignancies were excluded. All patients
underwent conventional HD for 4 hours per session three times
per week with synthetic membranes. We gathered data every
6 months for 5 years from September 2006 to September 2011.
This study was approved by the Institutional Review Board of
the Clinical Research Institute at Korea University Guro Hospital
(Seoul, Korea). All patients provided informed consent.
Clinical assessment
We investigated baseline demographic and clinical data such as
age, gender, presence of diabetes mellitus (DM), and body mass
index (BMI) at the time of enrollment. Laboratory data such as Hb,
iron metabolism indices (e.g., serum iron, total iron binding
capacity, transferrin saturation, and serum ferritin), serum albu-
min, serum creatinine, serum calcium, serum phosphorus, intact
parathyroid hormone (iPTH), and the single pool dialyzer clear-
ance (Kt) per volume (V) of ﬂuid (spKt/V) values were obtained at
the commencement of the study, and then every 6 months during
the follow-up period. For variables measured monthly, up to three
consecutive repeated measures in each session (6-monthintervals) were averaged to obtain one semiannual mean value
and to mitigate the effect of short-term variations. For variables
such as iPTH and spKt/V that were measured at 3-month intervals,
all available repeated measures in each session were used. Each
patient consequently may have had up to 10 repeated and
semiannual varying values for each measure during the 5-year
observation period. Observations with a missing value for any
measure were excluded from the analysis. We identiﬁed patients
who received kidney transplantation, changed to peritoneal
dialysis, or were transferred permanently to other clinics. We
included only available data from these patients.
The ESA doses were adjusted in accordance with the
national reimbursement policy of health insurance in Korea,
which only ﬁnancially supports the use of ESAs to treat anemia
in dialysis patients with a Hb levelr11 g/dL [10]. All-cause
mortality within a particular session was also assessed as an
outcome variable.
We divided the Hb values into six groups: (1) Hbo9 g/dL;
(2) 9 g/dLrHbo10 g/dL; (3) 10 g/dLrHb o11 g/dL; (4) 11 g/dL
rHbo12 g/dL; (5) 12 g/dLrHbo13 g/dL; and (6) HbZ13 g/dL).
A Hb level of 10–11 g/dL was the reference value.
Statistical analysis
We performed descriptive analysis to assess the baseline
characteristics of the study population. All results, except for
the iPTH values, are presented as the mean7the standard
deviation. Because the range of iPTH was so broad, it is
presented as the median of the 25th and 75th percentile values.
The generalized estimating equation with exchangeable corre-
lation structure was used to investigate its association between
the variables and mortality because the laboratory values mea-
sured at different time points in the same person were correlated.
To identify factors inﬂuencing mortality, univariate analysis was
performed for each demographic and laboratory variable. Multi-
variate analysis was performed to calculate the odds ratio of
mortality, based on the semiannual Hb level. Adjustment was
performed for signiﬁcant variables in univariate analysis, and
performed for other variables that affect survival or the Hb level
such as gender, BMI, and iron metabolism indices. Four models
were examined, based on the level of multivariate adjustment:
(1) the unadjusted base model (Model 1), which included Hb as
the predicting variable and all-cause mortality as the outcome
variable; (2) Model 2, which included adjustments for patient
demographics (i.e., age, sex, presence of DM, BMI); (3) Model 3,
which included adjustments for spKt/V, iron metabolism indices
(i.e., ferritin, transferrin saturation), and the variables in Model 2;
and (4) Model 4, which included adjustments for serum creati-
nine, serum albumin, serum phosphate, serum calcium-
phosphorus products, and the variables in Model 3. All laboratory
data were included as time-varying covariates with up to 10
semiannual averaged values per variable per patient.
All descriptive and multivariate statistics were performed
with SAS software, version 9.1 (SAS Institute Inc., Cary, NC,
USA). Statistical signiﬁcance was deﬁned as Po0.05.Results
Study population
This study included 362 patients whowere treated at 10 clinics
in western Seoul in September 2004. The overall follow-up time
Kidney Res Clin Pract 34 (2015) 20–2722was 1,162 patient-years. There were 95 (26.2%) deaths, which is a
death rate of 8.2 per 100 patient-years. The unadjusted analysis
(i.e., Model 1) included 2,277 patient sessions, and the ﬁnal
analysis (i.e., Model 3) included 1,119 patient sessions.Table 1. Baseline characteristics of the study population
Variable Total
(n¼362)
Age (y) 58.4712.8
Women 45.8
Diabetes mellitus 37.3
Body mass index (kg/m2) 21.773.3
Single pool Kt/V 1.5070.27
Initial laboratory values
Blood hemoglobin (g/dL) 10.171.1
Serum albumin (g/dL) 3.970.3
Serum creatinine (mg/dL) 9.372.7
Serum phosphorus (mg/dL) 5.171.6
Serum calcium (mg/dL) 8.870.8
Calcium-phosphorus products (mg2/dL2) 46.1714.6
iPTH (pg/mL) n 66.5 (34.0, 166.3)
Serum ferritin (ng/mL) 266.37237.2
Serum iron (ng/mL) 82.4735.8
TIBC (mg/dL) 208.2739.4
Transferrin saturation 40.2716.7
n The iPTH level is presented as the median (25th percentile, 75th
percentile).
Data are presented as % or mean7SD, unless otherwise indicated.
iPTH, intact parathyroid hormone; Kt/V, dialyzer clearance (Kt) per
volume (V) of ﬂuid; TIBC, total iron binding capacity; SD, standard
deviation.
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Table 2. Risk of all-cause mortality associated
Variable
Age
Gender
Diabetes mellitus
Body mass index (kg/m2)
Serum albumin (g/dL)
Serum creatinine (mg/dL)
Serum phosphorus (mg/dL)
Serum calcium (mg/dL)
Calcium-phosphorus products (mg2/dL2)
iPTH (pg/mL)
Serum ferritin (ng/mL)
Transferrin saturation (%)
n Indicates a signiﬁcant value (Po0.05).
CI, conﬁdence interval; iPTH, intact parathyroidTable 1 shows the demographic characteristics and basal
laboratory variables of the study population. The mean age
was 58.4712.8 years, and the proportion of male patients
(54.2%) was slightly larger than that of female patients (45.8%).
The mean BMI was 21.773.3 kg/m2. One hundred and thirty-
ﬁve (37.3%) patients were diagnosed as having DM.
Fig. 1 shows the frequency distribution of the average Hb
per patient session. The most common hemoglobin level
(42.2%) was 10–11 g/dL. The second most common Hb level
(24.9%) was 9–10 g/dL. Nearly 67.1% of patient sessions were
associated with a Hb level of 9–11 g/dL.Analysis of factors affecting patient survival
After adjusting for Hb level, the risk analysis of relevant
variables showed that age, presence of DM, serum creatinine,
serum albumin, serum phosphorus, and calcium-phosphorus
products had a statistically signiﬁcant inﬂuence on the odds
ratio of mortality (Table 2). However, gender, BMI, iron
metabolism indices, serum calcium, and iPTH had no signiﬁ-
cant effect. A young age, absence of DM, higher serum
creatinine, and high serum albumin were associated with
lower mortality. Higher serum phosphorus and calcium-
phosphorus products seemed to be associated with better
survival. However, the association was no longer signiﬁcant
after additional adjustments for age, BMI, serum creatinine,
and serum albumin (Table 3).18.1%
4.4%
2.0%
11–12 12–13 ≥13
in range (g/dL)
alues. The results are expressed as patient sessions.
with relevant variables
Odds ratio 95% CI P
1.04 1.02–1.06 <0.001*
1.13 0.74–1.72 0.569
1.37 1.06–1.92 0.035*
0.97 0.91–1.03 0.398
0.35 0.16–0.74 0.005*
0.83 0.76–0.89 <0.001*
0.78 0.67–0.92 0.003*
0.92 0.72–1.17 0.507
0.97 0.96–0.99 0.002*
0.99 0.99–1.00 0.611
1.00 1.00–1.01 0.102
1.00 0.98–1.02 0.936
hormone.
Table 3. Risk of all-cause mortality associated with serum phos-
phorus and calcium-phosphorus products, after adjusting for nutri-
tion markers
Variable Odds ratio 95% CI P
Serum phosphorus (mg/dL) 0.90 0.73–1.12 0.388
Calcium-phosphorus
products (mg2/dL2)
0.99 0.97–1.01 0.360
CI, conﬁdence interval.
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Jung et al / Optimal hemoglobin in HD patients 23Association of Hb with patient survival
An association between the semiannual average Hb value
and mortality within the same session was analyzed using the
generalized estimating equation model (Table 4). A Hb level of
10–11 g/dL was selected as the reference group. The base
model (i.e., Model 1) did not include adjustments for demo-
graphics or laboratory values. Additional models included
adjustment for demographics and relevant variables. Model
4 was adjusted in the same manner as Model 3 and adjusted
for variables that had a signiﬁcant inﬂuence on the odds ratios
of mortality, based on the Hb level (Table 2).
Using Models 1 and 2, a Hb level of 10–11 g/dL had a lower
mortality odds ratio than a Hb level of 11–12 g/dL. In Model 3,
the lowest mortality odds ratio—other than that of the group
with a Hb level413 g/dL—was observed in the Hb 10–11 g/dL
group. Model 4 showed similar results, except that comparing
the Hb 10–11 g/dL group with the Hbo9 g/dL group did not
show a statistically signiﬁcant difference.
Adjusting the demographic and laboratory values to those of
the base model resulted in changes in the mortality odds ratio
within Hb groups. However, the trend toward the Hb 10–11 g/dL
group having lower mortality than groups with Hb levelo13 g/dL
was maintained in all multivariate analyses (Fig. 2).Ta
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In a cohort of 362 Korean HD patients, we prospectively
collected repeated measures of laboratory values and assessed
the 6-month mortality risk associated with the Hb level. We
demonstrated that a Hb level of 10–11 g/dL (i.e., the reference
range) was associated with the lowest mortality risk among
the groups with Hb levelso13 g/dL. In all models, a Hb
levelZ13 g/dL was also associated with lower mortality than
the other Hb groups, except for the reference range group;
however, this result was not statistically signiﬁcant.
Several variables such as age, presence of DM, and dialysis
adequacy, which were considered to have an effect on survival,
were adjusted for in Models 2 and 3. Iron metabolism indices
associated with the Hb level were also adjusted for in Model 3.
The repeated measures that had a signiﬁcant inﬂuence on
mortality were used for the cumulative adjustment in Model 4
(Table 2). These measures were indicators of malnutrition and
inﬂammation and have been associated with important out-
comes in dialysis patients in previous studies [11,12].
The confounding effects of these variables and their
changes over time may be controlled for by adjustment. In
our results, the association between the Hb level and mortality
were not attenuated by adjusting for potential confounding
factors.
**
*
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Figure 2. Association between hemoglobin level and risk of all-cause mortality in the study population.
n Indicates a signiﬁcant value (Po0.05).
Kidney Res Clin Pract 34 (2015) 20–2724Early observational studies from 1993 to 1999 showed an
association between a low Hct level and increased mortality in
long-term dialysis patients, but showed no association
between increased mortality and a Hct value greater than
the reference group (i.e., Hct 33–36% or Hct 36–39%) [2,13]. At
that time, very few patients achieved a Hb level412 g/dL, and
erythropoietin use was much less frequent than its use in
the 2000s.
In the early 21st century, two observational longitudinal
studies by Regidor et al [14] and by Messana et al [15]
investigated the association between Hb/Hct level and mor-
tality in long-term HD patients by repeated measures. These
studies showed that a Hb level of 12–13 g/dL and a Hct level of
36–39% were associated with the greatest survival, after
adjusting for demographics, comorbidities, and time-varying
laboratory measures or medications. In these studies, Hb and
Hct levels less than or greater than the greatest survival range
(i.e., Hbo12–13 g/dL and Hct436–39%) were associated with
an increased mortality risk. In the study by Regidor et al [14],
most (93%) patients received ESAs, and patients who received
ESAs had Hb levels similar to patients who did not receive
ESAs (mean Hb, 12.071.3 g/dL versus 12.371.5 g/dL, respec-
tively) [14]. The study by Messana et al [15] showed that ESAs
were administered in more than 99% of patient sessions in
which patients had a Hb level413 g/dL [15]. These two studies
indicate that Hb levels413 g/dL may be achieved through ESA
therapy.
Several studies have suggested that a greater ESA dose at
higher Hb/Hct levels was associated with an elevated mortality
risk [16,17]. However, an independent association between the
dose of ESAs or ESA hyporesponsiveness and survival remain
to be determined [18].
In our study, Hb levels of 11–13 g/dL were associated with a
higher mortality risk, compared to the reference group. How-
ever, Hb levels413 g/dL did not show a statistically signiﬁcant
result. Hemoglobin levelsZ13 g/dL were found in only 46
measures, which is approximately 2% of the total patient
sessions. This count may have been too small to show a
statistical signiﬁcance.
In all models, the group with a Hb levelZ13 g/dL was also
associated with lower mortality, compared to the other Hbgroups, except for the reference range group. However, this
result was not statistically signiﬁcant. Thirty-seven (80.43%)
measures among Hb levelsZ13 g/dL had a previous measure
of Hb411 g/dL. Nearly all of these Hb levels may be achieved
naturally without ESA therapy, with regard to the national
reimbursement policy of health insurance in Korea [10]. In
recent studies, a normal Hb level (4 13 g/dL or412 g/dL) that
was not achieved by ESA was not a risk factor for mortality in
patients with CKD [18,19].
In contrast to the results of early observational studies, the
results of several randomized controlled trials (RCTs) using
ESAs for different target Hb levels have repeatedly demon-
strated an increased risk of mortality or no beneﬁt on
mortality or cardiovascular events in patients treated to
achieve higher Hb level [20–23]. These RCTs compared similar
Hb groups with a high Hb target of 13.0–15.0 g/dL and a low
Hb target of 9.0–11.5 g/dL.
Based on these results, the United States Food and Drug
Administration (FDA) in 2011 modiﬁed recommendations for
the dosing of ESAs in patients with CKD [24]. The new ESA
label recommends starting ESA when a Hb level iso10 g/dL
and using the lowest possible ESA dose required to reduce the
need for transfusions.
Several guidelines from international groups and various
countries are currently being updated. The guidelines propose
a Hb level of 10–12 g/dL as the target range. The optimal Hb
target in patients with CKD remains unclear; however the Hb
target range is lower than the range used in the past (Table 5).
This study was a longitudinal observational study that
calculated semiannual averaged Hb values and mortality in
the same session. The Hb range with the lowest mortality
(10–11 g/dL) was lower than the Hb target in the KDOQI
guidelines [8], but was in correspondence with the recent
trend toward a lower Hb target.
This study has several limitations. First, because we con-
ducted an observational study, the ﬁndings presented in this
report do not reﬂect a cause-and-effect relationship, but only
reﬂect associations. Therefore, we cannot rule out the possi-
bility that such associations were inﬂuenced by unmeasured
factors that contribute to anemia and survival such as under-
lying comorbidities or inﬂammation.
Table 5. Summary of recommendations for anemia in chronic kidney disease
Hb target ESA use
International guidelines
KDOQI 2007 n Hb level, 11.0–12.0 g/dL. The Hb target should
not beZ13.0 g/dL
—
KDIGO 2012 — Start ESAs when the Hb level is 9.0–10.0 g/dL to avoid Hb levelso9.0 g/dL. ESAs should not be used
for Hb levels411.5 g/dL. ESAs are not recommended for Hb levels413 g/dL
ERBP 2004 † Hb level,411 g/dL. In HD patients, a Hb
level414 g/dL is not desirable
—
2009 ‡ Hb level, 11–12 g/dL. The Hb level should
not intentionally be413 g/dL
—
2013 ‡ Hb level, 10–12 g/dL. The Hb level should
not be413 g/dL
Start ESAs when the Hb level is 9.0–10.0 g/dL to avoid a Hb levelo9.0 g/dL. ESAs should not
be used for Hb levels411.5 g/dL. ESAs are not recommended for Hb levels413 g/dL
National guidelines
KSN 2005 Hb level, 11.0–12.0 g/dL —
CSN 1999 Hb level, 11.0–12.0 g/dL —
2008 In HD and ND patients, a Hb level of 11.0 g/dL.
In PD patients, a Hb level of 10.0–12.0 g/dL
Initiate ESAs when Hb level iso10.0 g/dL; Prescribe ESAs to achieve the target Hb level
CARI 2008 Target Hb level, 11.0 g/dL. A target Hb413.0 g/dL
is inadvisable
—
2011 Hb level, 10.0–11.5 g/dL. A Hb level413.0 g/dL
is not recommended
In dialysis patients, ESAs can be used to prevent Hb levelso9.5 g/dL
UK Renal Association 2006 Hb level, 10.5–12.5 g/dL Adjust ESAs when the Hb levelso11 or412 g/dL to maximize the proportion of patients
in the range of 10.5–12.5 g/dL
2010 Hb level, 10–12 g/dL Adjust ESAs when Hb levels areo10.5 g/dL or411.5 g/dL to achieve a population
distribution centered on a mean of 11 g/dL in the range
of 10–12 g/dL
JSDT 2004 Hb level, 10–11 g/dL ESAs should be initiated when Hb levels areo10 g/dL
2008 In HD patients, Hb level of 10–11 g/dL. In PD and
ND patients, Hb level ofZ11 g/dL
In HD patients, ESAs should be adjusted when the Hb level is412 g/dL.
In PD and ND patients, adjustments to ESAs should be considered when the Hb level is413 g/dL
n Contents of the 2007 update of KDOQI anemia guidelines.
† Contents of European Best Practice Guidelines.
‡ Contents of the ERBP position statement.
CARI, Caring for Australasians with Renal Impairment; CKD, chronic kidney disease; CSN, Canadian Society of Nephrology; ERBP, European Renal Best Practice; ESAs, erythropoiesis-stimulating
agents; Hb, hemoglobin; HD, hemodialysis; JSDT, Japanese Society for Dialysis Therapy; KDIGO, Kidney Disease: Improving Global Outcomes; KDOQI, National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative; KSN, Korean Society of Nephrology; ND, nondialysis; PD, peritoneal dialysis.
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Kidney Res Clin Pract 34 (2015) 20–2726Second, our study enrolled a small number of patients,
compared to other studies. Previous observational studies
mentioned in this paper included at least 40,000 patients,
compared to our 362 patients [2,13–15].
Because of the discrepancy of the KDOQI guidelines [8] and
the reimbursement policy of Korea, ESAs were discontinued
and reinstituted frequently [25]. A third limitation therefore is
that it was difﬁcult to identify exact ESA doses and thus they
were not reported in this study.
Fourth, with the exception of DM, underlying diseases were
not included in the analysis.
Fifth, among variables that had a signiﬁcant inﬂuence on
mortality (Table 2), the results of serum phosphorus and
calcium-phosphorus products were inconsistent with previous
ﬁndings [11,26]. The results were also not statistically signiﬁ-
cant after additional adjustments for nutritional parameters
(Table 3). Therefore, it is possible that the inﬂuence of serum
phosphorus and calcium-phosphorus products on mortality
were caused by nutrition.
The strengths of our study are the following: (1) to the best
of our knowledge, this is the ﬁrst study in the 21st century to
investigate the association between the Hb level and mortality
in a contemporary cohort of Korean HD patients and (2) several
laboratory variables associated with patient outcome were
studied in the form of repeated measures of longitudinal data.
The Hb levels may change drastically over time, and the
management of patients with CKD is based on periodic
measurements of blood. Therefore, longitudinal measurement
of Hb and laboratory values, rather than measurements at only
one point in time, may provide additional insights.
In conclusion, we found that Hb levels of 10–11 g/dL were
associated with the lowest mortality among groups with Hb
levelso13 g/dL in Korean patients on maintenance HD. We
could not deﬁne the optimal Hb level because of the observa-
tional nature and small sample size of our study; therefore,
larger interventional trials are warranted to determine the
optimal Hb target for Korean HD patients.Conﬂict of interest
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